Prospective monitoring of biochemically recurrent prostate cancer (BCR) using prostate specific membrane antigen (PSMA) imaging: 21-month follow-up.
Ravi A. Madan(National Cancer Institute), Melissa L. Abel(National Institutes of Health), Katherine Lee-Wisdom(National Institutes of Health), Amy Hankin(National Institutes of Health), Laura A. Sena(Johns Hopkins University), Marijo Bilušić(National Institutes of Health), Choyke Pl(National Institutes of Health), Fatima Karzai(National Institutes of Health), Esther Mena(National Institutes of Health), Megan Hausler(National Institutes of Health), Liza Lindenberg(National Cancer Institute), Russell K. Pachynski, Jeanny B. Aragon-Ching(Virginia Cancer Institute), Monique Williams(National Institutes of Health), Helen Moon(National Cancer Institute), Deborah Jolissaint(Walter Reed National Military Medical Center), Catherine Handy Marshall(Johns Hopkins University), William D. Figg(National Institutes of Health), Gregory T. Chestnut(Walter Reed Army Institute of Research), Edwin M. Posadas(Cedars-Sinai Medical Center)
Cited by 0
Related Papers
Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors
|Clinical Cancer Research|2018|415
Cancer Survivorship—Genetic Susceptibility and Second Primary Cancers: Research Strategies and Recommendations
|JNCI Journal of the National Cancer Institute|2006|345
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
|The Lancet Oncology|2012|327
Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations
|Journal for ImmunoTherapy of Cancer|2018|314